PALLIATIVE TREATMENT OF ADVANCED LUNG CANCER WITH RADIOTHERAPY AND THAI HERBAL MEDICINE AS SUPPORTIVE REMEDY
Abstract
OBJECTIVE: To evaluate the supportive effect of Thai herbal medicine, Vilac Plus (G716/45) on standard palliative radiotherapy in advanced stage IIIB-IV lung cancer compare with historic control from the literature reports.
PATIENTS AND METHODS: Thirteen patients in advanced lung cancer stage IIIB-IV with poor performance status were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac Plus G716/45)
RESULTS: Thirteen patients (8 male, 5 female) in advanced stages lung cancer with poor performance status, stage IIIB 11 cases, stage IV 2 cases. Median age 66 years (range 44.4 -83 years). The pathological diagnosis were 5 cases of squamous cell carcinoma, 2 cases of adenocarcinoma, 1 case of bronchioalveolar carcinoma, 1 case of mixed squamous and adenocarcinoma and 4 cases of clinically advanced lung cancer as of evidenced by computed tomography chest scan/chest X-ray. The results of treatment 4-6 weeks after radiotherapy revealed 76.92% (10/13 cases) of clinically improvement and 23.08% (3/13 cases) of clinically stable. Overall response rate was 46.15% (6/13 cases) of partial response and 53.85% (7/13 cases) had shown stable diseases. Patterns of failure were found to be locally progressing 46.15% (6/13 cases) at the primary site, 30.77% (4/13 cases) at the locoregional, 23.08% (3/13 cases) at the locoregional with distant metastases. Median follow-up time is 18 months (range 7-50 months). Clinical benefit rate, evaluated at ≤ 15 months was 72.72%. However the median survival period analysis required longer follow-up and more detail assessment.
CONCLUSION: The results of this study are promising in the aspect of good quality of life and preferable because of the cost effectiveness to be used as an adjuvant for radiotherapy.
Downloads
Metrics
References
Suntorntanasat T, Banchonglikitkul C, Klungsupaya P, et al. Acute oral toxicity test Herbal tonic solution (G7 16/45) Thailand Institute of Scientific and Technological Research. (Written personal communications) September 2003, 1-8.
Amadi Pirasahid P, Suntorntanasat T. Analytical report on Herbal tonic solution (G716/45) Thailand Institute of Scientific and Technological Research. (Written personal communications) July 2004, 1-3.
Durand Phillippe, Prost Michel. In Vitro study of Vilac Plus analysis. Kirial International laboratories KRL Test (SPIRAL-No. Patent FR 2.642.526), 3 rue des Mardors 21560 COUTERNON, France. July 2006, 1-
Lee S-S, Wei Y-H, Chen C-F, et al. Antitumor effects of polysaccharides of Ganoderma lucidum. Proc Int Symposium Ganoderma Sci, Auckland, 27-29 April, 2001, 1-6
Murakami A, Jiwajinda S, Koshimizu k, et al. Screening for in vitro anti-tumor promoting activities of edible plant from Thailand. Cancer Letters 1995; 95: 139-14
Mountain, CF (1997) Revisions in the international system for staging lung cancer. Chest 111, 1710-1717
Mountain, CF (1986) A new international staging system for lung cancer. Chest [suppl] 89, 225S-233S
Bragg, DG (1994) The diagnosis and staging of primary lung cancer. Radiol Clin North Am 32, 1-14
Stitik, FP (1994) The new staging of lung cancer. Radiol Clin North Am 32, 635-647
M. Lyikesici, P. Yumuk, F. Dane et al. Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey. Lung Cancer official Scientific Publication of the international association for the study of lung cancer. Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona, Spain. 2005; 49 (2): p5249
R Huber, M. Schmidt, A Borgmeier et al. Weekly docetaxel and vinorelbine as second -line therapy in advanced non-small cell lung cancer. Lung Cancer official Scientific Publication of the international association for the study of lung cancer, Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona, Spain 2005; 49 (2) p. s248
S. Hasturk, N. hatabay, F Ece et al. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer. Lung Cancer official Scientific Publication of the international association for the study of lung cancer, Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona, Spain 2005 49(2): p S247.
M. Zimmermann, F. Luthi, A. Zouhair et al. Gefitinib (Iressa) as first-line therapy in advanced non-small lung cancer. Lung cancer official scientific publication of the international association for the study of lung cancer Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona, Spain 2005; 49 (2): p. S276.
Wake B, Taylor R, Sandercock J. Hyperfractionated/accelerated radiotherapy regimens for the treatment of non-small cell lung cancer. A systematic review of clinical and cost-effectiveness. West Midlands Health Technology Assessment Collaboration (WMHTAC); 2002 (DPHE Report No.35): 65. Search date 2001; primary sources Medline, Embase, it, Cochrane Library, reference lists, contact with experts in the field and Internet searches.
Hansen O, Paarup H, Sorensen P. et al. Curative radiotherapy of local advanced non-small-cell lung cancer. Eight years of experience from Odense. Ugeskr Laeger. 2005 Sep 12; 167 (37): 3497-502.
Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd. Search date 1991; Primary sources Medline; Cancerlit; hand searches of meetings abstracts, bibliographies of books, and specialist journals; consultation of trials registers of National Cancer Institute; UK Coordinating Committee for Cancer Research; the Union Internationale Contre le Cancer; and discussion with trialists.
Saunders M, Dische S, Barrett A, et al: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999, 52:137-148.
Sause W, Kolesar P, Taylor S, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117:358-364.
Jeremic B, Shibamoto Y, Acimov L, etal: Randomized trial of hyperfaractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995,13:452-458.
Ball D, Bishop J, Smith J, et al. : A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer : final report of an Australian multi-centre trial. Radiother Oncol 1999, 52:129-36.
Kawahara M, Kubota K, Furuse K. [Radiotherapy and chemotherapy for locally advanced non-small-cell lung cancer: report of a clinical trial and review of the literature. South Osaka Lung Cancer Chemotherapy Study Group]. Nihon Kyobu Shikkan Gakkai Zasshi 1993;31 Suppl:212-7.
Mirimanoff RO. Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): are view. Lung Cancer 1994;11 Suppl 3: S79-99.
Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005; 128: 3975-84.
Zwitter M. Comments on treatment strategy for locally advanced non-small cell lung cancer. Lung Cancer 2002;38 Suppl 3:S33-5.
Pesee M, Prathnadi P,Kirdporn S,et al. Palliative treatment of late stages of cancer with radiotherapy and Thai herbal medicine as supportive remedy (primary report of 4 cases). The asean journal of radiology, Bangkok, Thailand, 2003;9(3): 195-208.
Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990;160:207-11.
Emami B, Munzenrider JE, Lee DJ, Rene JB. Radical radiation therapy of advanced lung cancer: evaluation of prognostic factors and results of continuous and split course treatment. Cancer 1979;44:446-56.
Maddox AM, Valdivieso M, Lukeman J, Smith TL, Barkley HE, Samuels ML et al. Superior vena cava obstruction in small cell bronchogenic carcinoma. Clinical parameters and survival . Cancer 1983;52:2165-72.
Kim Y, Chongviriyaphan N, Liu C, Russell RM, Wang XD. Combined antioxidant (beta-carotene, alpha-tocopherol and ascorbic acid) supplementation increases the levels of lung retinoic acid and inhibits the activation of mitogen-activated protein kinase in the ferret lung cancer model. Carcinogenesis 2006;27:1410-9.
Knekt P. Vitamin E and smoking and the risk of lung cancer. Ann N Y Acad Sci 1993; 686: 280-7; discussion 287-8.
Le Marchand L, Yoshizawa CN, Kolonel LN, Hankin JH, Goodman MT. Vegetable consumption and lung cancer risk: a population-based case-control study in Hawaii. J Natl Cancer Inst 1989;81:1158-64.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)
